A Phase II Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Details
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-C3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
Eligibility
You can join if...
Inclusion Criteria
Provision of signed informed consent (obtained according to institutional guidelines)
prior to initiation of any study-related procedures.
-Age >18 years at the time of informed consent.
-Histologically or cytologically diagnosed high-grade serous ovarian, fallopian tube, or
primary peritoneal cancer.
Exclusion Criteria:
Any of the following treatment interventions within the specified time frame prior to C1D1:
a. Major surgery within 28 days (any surgical incision should be fully healed prior to study drug administration).
b. Any chemotherapy or targeted tumor therapy within 14 days or 5 half-lives (whichever is shorter).
c. Radiation therapy within 21 days; however, if the radiation portal covered ≤5% of the bone marrow, the subject is eligible irrespective of the end date of radiotherapy.